12:00 AM
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Latuda lurasidone: Additional Phase III data

Additional data from the double-blind, international Phase III PREVAIL 2 trial in 505 patients with bipolar I depression showed that both once-daily 20-60 and 80-120 mg Latuda as monotherapy significantly reduced MADRS scores from baseline to week 6, the primary endpoint, by 15.4 points vs. 10.7 points for placebo (p<0.001 for both). On secondary endpoints, low- and high-dose Latuda significantly reduced CGI-BP-S scores from baseline to week 6 by 1.8 and 1.7 points, respectively, vs. 1.1 points for placebo (p<0.001 for both), and significantly reduced HAM-A scores by 6.8 and...

Read the full 430 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >